1) KRYSTAL-7 update on pembro+adagrasib in 1st line pdl1 >50% nsclc. Tox to navigate but mPFS >27m! Further reinforcing the view that ras orchestrates TME, not just cancer cell intrinsic pathways. Massive congrats to investigators, mirati, bms #ELCC25
27.03.2025 16:03 — 👍 6 🔁 5 💬 0 📌 0
2) daraxonrasib (rmc-6236) offering early phase and v impressive activity in g12d g12v 2nd line nsclc. RR 38% and mPFS >10m. V tolerable toxicity profile again. Next will be IO combos, congrats+++ to Revolution Medicines and the investigators. #ELCC25
27.03.2025 16:08 — 👍 4 🔁 3 💬 0 📌 0
Agree. A packed room for SCLC on the last day of a conference? Unheard of previously! Obviously all attending to listen to @annaminchom.bsky.social , @drjnaidoo.bsky.social ,& @stephenvliu.bsky.social!
@btog.bsky.social #BTOG25
05.03.2025 13:49 — 👍 13 🔁 5 💬 0 📌 0
Poster session absolutely packed:
Loud, energetic, crowded
Brilliant ❤️
03.03.2025 19:19 — 👍 2 🔁 2 💬 0 📌 0
A great talk Adam, really enjoyed hearing about the breadth of your work!
03.03.2025 18:38 — 👍 3 🔁 2 💬 1 📌 0
The Welcome and Updates session will be chaired by @DrSanjayPopat, with Neal Navani,
Rolf Stahel and Thierry Berghmans speaking. #BTOG25
03.03.2025 16:40 — 👍 2 🔁 1 💬 0 📌 0
ALK+ UK is off to @btog.bsky.social next week - a key event in #lungcancer - Debra Montague (Chair) & Geoff Otterman (Treasurer) are attending.
We’re delighted to have 2 abstracts accepted for presentation.
Looking forward to learning, connecting, & sharing patient perspectives. #BTOG25 #LCSM
26.02.2025 07:46 — 👍 9 🔁 3 💬 1 📌 0
Delighted that our #BTOG25 Annual Conference keynote speaker is Pasi Jänne, translational thoracic medical oncologist at the Dana Farber Cancer Institute & professor of medicine at Harvard Medical School. Topic: “Novel strategies to targeting drug tolerant persistent state in lung cancer.” #LCSM
11.02.2025 17:25 — 👍 6 🔁 1 💬 0 📌 0
Looking forward to it!
25.01.2025 17:59 — 👍 1 🔁 0 💬 0 📌 0
@annaminchom.bsky.social and I will be doing a very slow jog on Tuesday am at ECMC JING meeting. Meet in foyer around 7am. Plenty of time for it to be a social jog, shower and breakie before we begin day 2. Can’t wait (for the meeting)!
25.01.2025 11:40 — 👍 3 🔁 2 💬 1 📌 0
www.icr.ac.uk/about-us/icr... Blog about projects @icrlondon.bsky.social in ovarian cancer. Its only the tip of the iceberg, there are many exciting projects too early to talk about! Blessed to be a small cog in the big wheel of progress in cancer research at my institution and beyond…
24.01.2025 06:16 — 👍 5 🔁 5 💬 0 📌 0
Amazing to see recent NICE approvals:
1. Neoadjuvant alone (CM816): all PDL1
2. Perioperative (KN671, AGEAN) : all PDL1
3. Adjuvant (IMP010, TPS 50+; KN091 all PDL1)
4. Adjuvant EGFRm (ADAURA)
5. Adjuvant ALK+ (ALINA)
Biomarker testing in early #NSCLC now critical!
21.12.2024 10:43 — 👍 22 🔁 7 💬 1 📌 2
The leading thoracic cancer clinical trials group in Australia and New Zealand
The National Lung Cancer Audit (NLCA) is part of the National Cancer Audit Collaborating Centre (NATCAN).
The aim of the NLCA is to evaluate the patterns of care and outcomes for patients with lung cancer in England and Wales.
#LungCancer #OncSky #oncosky
We are the Investigator Initiated Trials team within the
@icr.ac.uk Drug Development Unit. We sponsor innovative Phase I trials of novel anti-cancer agents.
Medical oncologist interested in RAS targeting and improving lung cancer.
Weegie in Stockport, David Byrne fan, Francophile.
Consultant Pharmacist - Genomic Medicine at North Thames Genomic Medicine Service Alliance and Specialist Oncology Pharmacist - Lung Cancer at Royal Marsden Hospital
Pharmacogenomics; Pharmacy; Oncology; Books & Coffee
Views are my own 🤓
☕️📚🍂
Thoracic Oncologist, Guys Cancer, London
Lung Medical Oncology Consultant and SACT clinical service lead at Guy’s and St Thomas’ hospital Loddon UK, Honorary Senior Lecturer King’s College London
Thoracic Medical Oncologist and Honorary Clinical Lecturer. Liverpool, England, UK.
In Silico Medicinal Chemistry at the Institute of Cancer Research
💻💊 Using computational chemistry to support projects within the Centre for Cancer Drug Discovery!
📍 London, UK
Cell biologist and drug discovery scientist with Cancer Research Horizons. Based at the CRUK Scotland Institute in Glasgow.
Group Leader, Induced Proximity Therapeutics, Centre for Protein Degradation, Institute of Cancer Research, London
A book club run by UK oncologists Anthea & Nicola. Alternates between medical &
Non-medical themes. Open to everyone (you don’t have to work in oncology!)
Discussions happen on zoom every few months!
Cell Death and Immunity Laboratory. We are interested in the mechanisms of #Apoptosis, #Necroptosis and #Inflammation in #Cancer. Posts by @ttenev.bsky.social
Lead at NHS England for #LivingWithAndBeyondCancer.
Trustee of the Pelvic Radiation Disease Association PRDA.org.uk | Views my own | Quality of life really matters
• Medical physicist @ The Royal Marsden ☢️
• Non-native English speaker 🇧🇷
• Londoner 🇬🇧
All views my own
Patient-driven organization seeking a cure and working to improve patients' quality of life and life expectancy worldwide.
🔬 Advancing Research. Empowering Patients. Championing Advocacy.
We’re patients & families dedicated to improving outcomes for people with oncogene-driven lung cancer through education, support, and powering cutting-edge research.
Welcome to the official Bluesky account for the New England Journal of Medicine. Follow for high-quality, peer-reviewed research and clinical content from the world’s leading medical journal, online at NEJM.org.
Follow @ai.nejm.org for medical AI content.
